Product
177Lu-DOTA-TATE
1 clinical trial
5 indications
Indication
Clinical TrialIndication
Phase IIndication
Neuroendocrine TumorsIndication
ThymomaIndication
MesotheliomaClinical trial
Phase I Trial With 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive TumoursStatus: Active (not recruiting), Estimated PCD: 2024-06-30